These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 28263921)

  • 1. The Impact of Splenectomy in Myelofibrosis Patients before Allogeneic Hematopoietic Stem Cell Transplantation.
    Robin M; Zine M; Chevret S; Meignin V; Munoz-Bongrand N; Moatti H; Xhaard A; Sicre de Fontbrune F; Peffault de Latour R; Sarfati E; Socié G
    Biol Blood Marrow Transplant; 2017 Jun; 23(6):958-964. PubMed ID: 28263921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome of transplantation for myelofibrosis.
    Ballen KK; Shrestha S; Sobocinski KA; Zhang MJ; Bashey A; Bolwell BJ; Cervantes F; Devine SM; Gale RP; Gupta V; Hahn TE; Hogan WJ; Kröger N; Litzow MR; Marks DI; Maziarz RT; McCarthy PL; Schiller G; Schouten HC; Roy V; Wiernik PH; Horowitz MM; Giralt SA; Arora M
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):358-67. PubMed ID: 19879949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment.
    Gergis U; Kuriakose E; Shore T; Mayer S; Mark T; Pearse R; Schuster M; Feldman E; Roboz G; Ritchie E; Scandura J; Wang H; Zhou XK; Silver RT; van Besien K
    Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):297-303. PubMed ID: 27025789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Splenectomy in Myelofibrosis: Indications, Efficacy, and Complications.
    Malato A; Rossi E; Tiribelli M; Mendicino F; Pugliese N
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):588-595. PubMed ID: 32482540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis.
    Ditschkowski M; Elmaagacli AH; Trenschel R; Gromke T; Steckel NK; Koldehoff M; Beelen DW
    Haematologica; 2012 Oct; 97(10):1574-81. PubMed ID: 22491742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Splenic irradiation as a component of a reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in myelofibrosis with massive splenomegaly.
    Ito T; Akagi K; Kondo T; Kawabata H; Ichinohe T; Takaori-Kondo A
    Tohoku J Exp Med; 2012 Dec; 228(4):295-9. PubMed ID: 23117264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic hematopoietic cell transplantation in patients with myelofibrosis: A single center experience.
    Schmohl JU; Groh C; Faul C; Vogel W; Möhle R; Wirths S; Schneidawind D; Kanz L; Bethge WA
    Ann Hematol; 2016 May; 95(6):973-83. PubMed ID: 27021303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Splenectomy and hemopoietic stem cell transplantation for myelofibrosis.
    Li Z; Gooley T; Applebaum FR; Deeg HJ
    Blood; 2001 Apr; 97(7):2180-1. PubMed ID: 11286221
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation.
    Gagelmann N; Eikema DJ; de Wreede LC; Koster L; Wolschke C; Arnold R; Kanz L; McQuaker G; Marchand T; Socié G; Bourhis JH; Mohty M; Cornelissen JJ; Chevallier P; Bernasconi P; Stelljes M; Rohrlich PS; Fanin R; Finke J; Maertens J; Blaise D; Itälä-Remes M; Labussière-Wallet H; Robin M; McLornan D; Chalandon Y; Yakoub-Agha I; Kröger N;
    Biol Blood Marrow Transplant; 2019 Jun; 25(6):e204-e208. PubMed ID: 30930192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen.
    Ali H; Aldoss I; Yang D; Mokhtari S; Khaled S; Aribi A; Afkhami M; Al Malki MM; Cao T; Mei M; O'Donnell M; Salhotra A; Pullarkat V; Yang L; Stein AS; Marcucci G; Forman SJ; Nakamura R; Pillai R; Snyder D
    Blood Adv; 2019 Jan; 3(1):83-95. PubMed ID: 30622146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Role of splenectomy in the treatment of myelofibrosis].
    Melikian AL; Kolosova LIu; Sokolova MA; Kovrigina AM; Silaev MA; Giliazitdinova EA; Gemdzhian ÉG; Karagiulian SR
    Ter Arkh; 2013; 85(8):69-76. PubMed ID: 24137967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stem cell transplantation for myelofibrosis: a report from two Canadian centers.
    Daly A; Song K; Nevill T; Nantel S; Toze C; Hogge D; Forrest D; Lavoie J; Sutherland H; Shepherd J; Hasegawa W; Lipton J; Messner H; Kiss T
    Bone Marrow Transplant; 2003 Jul; 32(1):35-40. PubMed ID: 12815476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
    Robin M; Tabrizi R; Mohty M; Furst S; Michallet M; Bay JO; Cahn JY; De Coninck E; Dhedin N; Bernard M; Rio B; Buzyn A; Huynh A; Bilger K; Bordigoni P; Contentin N; Porcher R; Socié G; Milpied N
    Br J Haematol; 2011 Feb; 152(3):331-9. PubMed ID: 21133885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).
    Patriarca F; Bacigalupo A; Sperotto A; Isola M; Soldano F; Bruno B; van Lint MT; Iori AP; Santarone S; Porretto F; Pioltelli P; Visani G; Iacopino P; Fanin R; Bosi A;
    Haematologica; 2008 Oct; 93(10):1514-22. PubMed ID: 18728030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation.
    Ciurea SO; Sadegi B; Wilbur A; Alagiozian-Angelova V; Gaitonde S; Dobogai LC; Akard LP; Hoffman R; Rondelli D
    Br J Haematol; 2008 Apr; 141(1):80-3. PubMed ID: 18324970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Allogeneic bone marrow transplantation for primary myelofibrosis after splenectomy].
    Sakashita C; Akiyama H; Mori S; Ohashi K; Sakamaki H
    Rinsho Ketsueki; 2000 Mar; 41(3):206-11. PubMed ID: 10774249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis.
    Lissandre S; Bay JO; Cahn JY; Porcher R; Cacheux V; Cabrespine A; Cornillon J; Cassinat B; Peffault de Latour R; Socie G; Robin M
    Bone Marrow Transplant; 2011 Apr; 46(4):557-61. PubMed ID: 21042309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction.
    Barosi G; Ambrosetti A; Buratti A; Finelli C; Liberato NL; Quaglini S; Ricetti MM; Visani G; Tura S; Ascari E
    Leukemia; 1993 Feb; 7(2):200-6. PubMed ID: 8426474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic hematopoietic stem cell transplantation for myelofibrosis.
    Barosi G; Bacigalupo A
    Curr Opin Hematol; 2006 Mar; 13(2):74-8. PubMed ID: 16456372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Splenectomy following JAK1/JAK2 inhibitor therapy in patients with myelofibrosis undergoing allogeneic stem cell transplantation.
    Barabanshikova MV; Zubarovsky IN; Savrasov VM; Korolkov AJ; Baykov VV; Botina AV; Vlasova JJ; Moiseev IS; Darskaya EI; Morozova EV; Afanasyev BV
    Hematol Oncol Stem Cell Ther; 2019 Sep; 12(3):140-145. PubMed ID: 30978308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.